A biopharma company and a joint venture have turned to the Delaware federal court to seek what it says is its fair share of the billions of dollars in profit generated from Moderna’s COVID-19 vaccine.

A complaint filed Monday alleges Moderna couldn’t have produced its vaccine as fast as it did without Pennsylvania-based Arbutus Biopharma Corp.’s patented mRNA delivery method and says Moderna didn’t ask for permission to license six patents involving nucleic acid-lipid particles, all of which are owned by Arbutus and have exclusive rights held by plaintiff Genevant Sciences GmbH, a Swiss joint venture between Arbutus and Roivant Sciences.